Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000233976 | SCV000291134 | uncertain significance | Lymphedema, primary, with myelodysplasia; Dendritic cell, monocyte, B lymphocyte, and natural killer lymphocyte deficiency | 2015-12-16 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid with asparagine at codon 46 of the GATA2 protein (p.Asp46Asn). The aspartic acid residue is highly conserved and there is a small physicochemical difference between aspartic acid and asparagine. This variant is present in population databases (rs370750401, ExAC 0.002%) but has not been reported in the literature in individuals with a GATA2-related disease. Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, this is a rare missense change with uncertain impact on protein function. There is no indication that this variant causes disease, but the evidence is insufficient at this time to prove that conclusively. Therefore, it has been classified as a Variant of Uncertain Significance. |
Institute of Human Genetics, |
RCV001262682 | SCV001440633 | uncertain significance | Dendritic cell, monocyte, B lymphocyte, and natural killer lymphocyte deficiency | 2019-01-01 | criteria provided, single submitter | clinical testing |